Prevalidation of a model for predicting acute neutropenia by colony forming unit granulocyte/macrophage (CFU-GM) assay

Toxicology in Vitro

Volumn 15, Issue 6, 2001, Pages 729-740

  Pessina, A ^a   Albella, B ^b   Bueren, J ^b   Brantom, P ^c   Casati, S ^d   Gribaldo, L ^d   Croera, C ^a   Gagliardi, G ^a   Foti, P ^a   Parchment, R ^e   Parent Massin, D ^f   Sibiril, Y ^f   Van Den Heuvel, R ^g  

^a Institute of Medical Microbiology   (Italy)

^b CIEMAT   (Spain)

^c TNO BIBRA International Ltd   (United Kingdom)

^d JOINT RESEARCH CENTRE   (Italy)

^e WAYNE STATE UNIVERSITY   (United States)

^f ESMISAB   (France)

^g FLEMISH INSTITUTE FOR TECHNOLOGICAL RESEARCH VITO   (Belgium)

Author keywords

Acute neutropenia; CFU GM assay; Drug haematotoxicity; Prediction model; Prevalidation

Indexed keywords

2 (2 DIMETHYLAMINOETHYL) 9 METHOXY 5 NITROPYRAZOLO[3,4,5 KL]ACRIDINE; 3' DEAMINO 3' MORPHOLINODOXORUBICIN; ANTINEOPLASTIC AGENT; DOXORUBICIN; FLAVOPIRIDOL; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; INTERLEUKIN 6; PACLITAXEL; STEM CELL FACTOR; TOPOTECAN; XENOBIOTIC AGENT;

ACCURACY; ACUTE DISEASE; ANIMAL CELL; ARTICLE; BONE MARROW CELL; BONE MARROW SUPPRESSION; CELL COUNT; COLONY FORMING UNIT GM; CONTROLLED STUDY; EXPERIMENTAL MODEL; HEMATOPOIESIS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INTERMETHOD COMPARISON; LABORATORY; LINEAR SYSTEM; MAXIMUM TOLERATED DOSE; METHODOLOGY; NEUTROPENIA; NEUTROPHIL; NONHUMAN; PREDICTION; REPRODUCIBILITY; STANDARD; UMBILICAL CORD BLOOD; VALIDATION PROCESS; XENOBIOTIC METABOLISM;

ACUTE DISEASE; ANIMALS; BONE MARROW CELLS; CELL COUNT; COLONY-FORMING UNITS ASSAY; DOGS; FETAL BLOOD; GRANULOCYTES; HUMANS; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MODELS, BIOLOGICAL; NEUTROPENIA; PREDICTIVE VALUE OF TESTS; RATS; RATS, INBRED F344; REPRODUCIBILITY OF RESULTS; XENOBIOTICS;

EID: 0034762255     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0887-2333(01)00085-6     Document Type: Article

References (35)

1. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts
2. Practical aspects of the validation of toxicity test procedures
3. The growth of mouse bone marrow cells in vitro
4. The role of prevalidation and validation in the development, validation and acceptance of alternative methods (the first report of ECVAM Task Force of Prevalidation)
5. Bone marrow colony-forming assays
6. Anthracycline and anthracenediones
7. Differential single-versus double-strand DNA breakage produced by doxorubicin and its morpholinyl analogues
8. Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells
9. Phase I study of taxol administered as a short i.v. infusion daily for 5 days
10. The use of in vitro systems for evaluating haematotoxicity. The report of recommendations of ECVAM workshop 14
11. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer
12. Direct growth suppression of myeloid bone marrow progenitor cells but not cord blood progenitors by human cytomegalovirus in vitro
13. Cellular model for drug interactions on hematopoiesis: The use of human umbilical cord blood progenitors as a model for the study of drug-related myelosuppression of normal hematopoiesis
14. Standardisation of the CFU-GM assay using hematopoietic growth factors
15. Phase I clinical trial of pyrazoloacridine NSC366140 (PD1 15934)
16. Variations in culture pH affect the cloning efficiency and differentiation of progenitors cells in ex vivo haemopoiesis
17. Haemopoietic colonies
18. Usefulness of the in vitro bone marrow colony forming assay in cellular toxicology
19. Methoxymorpholino doxorubicin (FCE 23762): Preclinical characteristics and first clinical experience
20. Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests
21. Roles for in vitro myelotoxicity tests in preclinical drug development and clinical trial planning
22. Human hematopoietic stem cells: Laboratory assessment and response to toxic injure
23. In vivo-in vitro correlation of myelotoxicity of 9-Methoxypyrazoloacridine (NSC-366 140, PD 115934) to myeloid and erythroid hematopoietic progenitors from human, murine and canine marrow
24. Alternative testing systems for evaluating non-carcinogenic, hematologic toxicity
25. In vitro toxicity of trichothecenes on rat haematopoietic progenitors
26. Investigational Anticancer Agents
27. The granulocyte macrophage colony-forming unit assay
28. Responsiveness of highly enriched CPU-GM subpopulations from bone marrow, peripheral blood, and cord blood to hemopoietic growth inhibitors
29. Antimicrotubule agents
30. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms
31. Haematotoxicity testing in vitro using human cord blood haematopoietic cells
32. Phase I clinical and pharmacokinetic study of Y-deamino-3′-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762)